Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Guidance Documents Regulation International

Global Pharma Guidance Tracker – April 2023

  • Data

Executive Summary

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

You may also be interested in...



Singapore To Require GMP Evidence On Chemical Substance Drug Manufacturers

Singapore is taking steps to align good manufacturing practice requirements for chemical and biologic drug substance manufacturers and has rolled out a one-year transition plan for compliance.

EU Advances Plans For New Catalogs Of RWD Sources & Non-Interventional Studies

Users of the new catalogs will benefit from a modern technology with enhanced view, search, export and data submission functionalities, says the European Commission.

WHO Seeks Feedback On Gaps In Current QA & GMP Guidelines

The World Health Organization has shortlisted over 30 quality assurance and good manufacturing practice guidelines that are over seven years old or need a major review.

Table

View full table

Topics

Tags:
Guidance Documents Regulation International
Latest Headlines

US FDA’s October Outlook: Xphozah After Dispute, Santhera’s New Steroid For DMD, & Plenty Of Pfizer

Can Medicare Cover Obesity Drugs Without Congressional Action? Industry Builds Its Case

Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings

Increase In Subpar Pharmaceutical Repacking Draws US FDA Attention

See All
UsernamePublicRestriction

Register

PS148160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By